Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07224477 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of V540A in Healthy Female Participants (V540A-005)

StatusWithdrawn
PhasePhase 2
Started2026-07-20
View on ClinicalTrials.gov ↗

Amendment history

2026-09-09
Study Status, Study Design v3
Withdrawn before enrolling
Trial withdrawn: Business Reasons
Enrollment targetestimated 525→confirmed 0
2026-02-17
Study Status v2
Re-verified, no change to tracked fields
2025-12-23
Study Status v1
Primary completion date2026-11-16→2028-04-04
Completion date2026-11-16→2028-04-04
Start date2025-12-05→2026-07-20
2025-11-03
Original filing
Merck (MSD)
401 trials monitored
See 24 trials at risk
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. A standard vaccine to prevent HPV-related cancers is V503. V503 protects against 9 types of HPV. V540A is a study vaccine designed to protect against the same (shared) 9 HPV types plus other (unique) HPV types. Researchers want to learn if V540A: * Is safe and if people tolerate it * Works as well as V503 to cause an immune response (the body's response to protect against infections and illnesses) to the shared HPV types.
Trial Details
NCT Number NCT07224477
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Start Date 2026-07-20
Primary Completion 2028-04-04 (estimated)
Study Completion 2028-04-04 (estimated)
Updated on ClinicalTrials.gov 2026-09-14